Shots:
- Akeso has enrolled the first patient in the P-Ib/II (AK138D1-202) study assessing its AK138D1 monotx. or in combination with ivonescimab for the treatment of advanced breast cancer
- The trial is evaluating AK138D1 in 2 breast cancer subtypes: HR+/HER2- & triple-negative breast cancer. The study incl. pts ranging from treatment-naïve to heavily pretreated & enrolls participants across a broad spectrum of PD-L1 expression levels
- AK138D1 is the HER3-targeting ADC, designed to reduce uptake in normal tissues & minimize off-target toxicities. Its differentiated in-house platform aims to enhance safety & expand the therapeutic window while maintaining potent anti-tumor activity
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso Reports the NMPA Approval of Gumokimab to Treat Plaque Psoriasis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
